SynKIR-310 for Relapsed/Refractory B-NHL

Inclusion Criteria:

• Adult 18 years of age and older.

• Histologically confirmed diagnosis of B-NHL before enrollment.

• Must have received prior CAR T or were unwilling/unable to receive prior CAR T.

• Must have refractory or relapsed disease after receiving 2 prior lines of therapies.

• If relapsed/refractory post-auto-SCT, then must have undergone auto-SCT at least 6months prior to enrollment.

• If relapsed/refractory disease after allogeneic stem cell transplant (allo SCT) thenmust have undergone allo-SCT at least 6 months prior to enrollment and withoutevidence of graft versus host disease.

• Measurable disease at time of enrollment: At least one measurable lesion per LuganoResponse Criteria (Cheson et al., 2014).

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1

Exclusion Criteria:

• Previously treated with any investigational agent within 30 days prior to screening.

• Adequately treated non-melanoma skin cancer such as basal cell or squamous cellcarcinoma

• Carcinoma-in-situ (e.g., cervix, bladder, breast) treated curatively and withoutevidence of recurrence for at least 3 years prior to enrollment.

• Any other malignancy which has been completely treated and remains in completeremission for ≥ 5 years prior to enrollment. Completely treated prostate cancer withprostate-specific antigen (PSA) level < 1.0 may also be permitted.

• Known immunodeficiency disease.

• History or presence of active or clinically relevant primary central nervous system (CNS) disorder, such as seizure, encephalopathy, cerebrovascularischemia/hemorrhage, cerebellar disease, or any autoimmune disease with CNSinvolvement. For primary CNS disorders that have recovered or are in remission,participants without recurrence within 2 years of planned study enrollment may beincluded.

• Uncontrolled hypertension, history of myocarditis or congestive heart failure,unstable angina, serious uncontrolled cardiac arrhythmia, or myocardial infarctionwithin 6 months prior to study entry.

• Any active uncontrolled systemic fungal, bacterial or viral infection.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.